European advisory group backs Roche’s entrectinib

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Roche’s (OTCQX:RHHBY) Rozlytrek (entrectinib) for the treatment of patients with solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion or patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).

A final decision from the European Commission usually takes ~60 days.

https://seekingalpha.com/news/3578603-european-advisory-group-backs-roches-entrectinib